Hybrid Systems Modeling of Donor T-Cell Responses and Graft-Versus-Host-Disease After Posttransplantation Cyclophosphamide Administration.

Hsuan-Hao Fan, Jeannine S McCune, Christopher G Kanakry, Donald E Mager

Abstract read

In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hsuan-Hao FanDivision of Pharmacokinetics-Pharmacodynamics and Systems Pharmacology, Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, New York, USA.ORCID https://orcid.org/0000-0002-7428-1349

Jeannine S McCuneDepartment of Hematologic Malignancies Translational Science, City of Hope, Duarte, California, USA.ORCID https://orcid.org/0000-0002-0795-497X

Christopher G KanakryCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-7736-2056

Donald E MagerDivision of Pharmacokinetics-Pharmacodynamics and Systems Pharmacology, Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, New York, USA.ORCID https://orcid.org/0000-0002-4848-0440

Funding

Optimizing GVHD Prevention with Systems Pharmacology ModelsU01CA239373 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI HORNE, DAVID A., MAGER, DONALD E · 2019 to 2023

$3.0M

Intramural Research Program of the National Cancer Institute of the National Institutes of HealthNIH HHS U01CA239373

6 · The paper itself

Abstract

The optimal post-transplant cyclophosphamide (PTCy) dose to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplant (HCT) is undefined. Data from a novel murine HLA-haploidentical HCT model suggested that PTCy has a dose-dependent effect associated with its efficacy in preventing GVHD, including reduced proliferation of conventional CD4

Indexed as

CyclophosphamideGraft vs Host DiseaseHematopoietic Stem Cell TransplantationImmunosuppressive AgentsT-LymphocytesAnimalsDisease Models, AnimalDose-Response Relationship, DrugHumansMiceModels, BiologicalT-Lymphocytes, RegulatoryCyclophosphamideImmunosuppressive Agentscyclophosphamidegraft‐versus‐host diseasehematopoietic cell transplantpharmacokineticsquantitative systems pharmacology

Identifiers

PMID41979099

DOI10.1002/psp4.70252

PMCPMC13274751

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.